Mississippi lawmakers are set to consider allowing clinical trials into the therapeutic potential of the psychedelic ibogaine in the treatment of serious mental health conditions.
A joint hearing of the House and Senate Public Health and Human Services Committees will take place on August 28, spearheaded by the House panel’s chairman Rep. Sam Creekmore (R).
The intent is to start the conversation about alternative treatment options for people with mental health conditions, particularly for military veterans experiencing post-traumatic stress disorder (PTSD) and addiction.
Creekmore said the hearing is part of an “important effort to bring wellness, healing, and recovery to Mississippians.”
The chairman said that the hearing will help inform legislation he’s planning to introduce legislation, which he said is largely modeled after a bill that passed the Texas legislature and was signed into law in June.
That measure will create a state-backed research consortium to conduct clinical trials on ibogaine as a possible treatment for substance use disorders and other mental health conditions. The ultimate goal of the project is to develop the psychedelic into a prescription drug with U.S. Food and Drug Administration (FDA) approval.
“This is a critical step forward in our commitment to not just talk
Read full article on Marijuana Moment
